When comparing semaglutide and tirzepatide, the experimental system should be reported in full, including receptor construct, receptor species, host-cell background, receptor-expression level where available, assay platform, incubation time, concentration range, protein-binding conditions, normalization method, reference ligand, and statistical model
No dose, schedule, or administration instruction appears anywhere below those are outside the scope of a research-use article
Similarly, a post-hoc analysis of SURPASS-1, enrolling 478 patients with T2D, found that all doses of tirzepatide as monotherapy increased insulin sensitivity compared to placebo, as suggested by the decreases in HOMA2-IR by 923% (vs +14.7% with placebo) and fasting insulin levels by 212% (vs +15%) and the increase in adiponectin by 1623% (vs 0.2%) and IGFBP-2 by 3870% (vs +4.1%) at 40 weeks [76]
Biweekly or Monthly Injections: For ongoing maintenance or prevention of deficiency